Which GLP-1 Medications Should a Weight Loss Clinic Offer?

A weight loss clinic should generally evaluate Wegovy and Wegovy HD (semaglutide) and Zepbound (tirzepatide) as core FDA-approved weight-management options, with Saxenda (liraglutide) as a possible alternative. The final formulary depends on labeled indications, clinical review, supply, pharmacy operations, payer behavior, state rules, and the clinic’s advertising controls—not simply product popularity.

FDA-approved GLP-1 options: at-a-glance comparison

The table is a formulary-planning comparison, not a recommendation for any individual patient. Independently licensed clinicians must decide whether a medication is medically appropriate, what product is prescribed, and what monitoring is required.

What should a telehealth weight loss formulary include?

A defensible GLP-1 formulary should begin with products whose FDA labeling matches the program’s intended population and services. It should then connect each product to a clinical pathway, pharmacy workflow, state operating model, and marketing review process.

For many adult programs, that means evaluating Wegovy or Wegovy HD and Zepbound as core products. Saxenda can serve as an alternative where the clinic wants a liraglutide option or a labeled adolescent pathway. This structure is not a clinical directive; it is a business framework for ensuring that the products a clinic discusses, contracts around, and advertises are aligned with their approved labeling.

A clinic should document at least these distinctions:

• FDA-approved indication for the specific product.
• Patient population covered by that indication.
• Relevant warnings, contraindications, and product-specific restrictions.
• Whether the intended service is general weight management or a specialty pathway such as cardiovascular-risk reduction, MASH, or obstructive sleep apnea.
• Who makes the prescribing decision.
• Which pharmacy fulfills the prescription and under what state and contractual conditions.
• How availability, recalls, adverse events, and substitutions are handled.

This is different from building a menu around active ingredients alone. Ozempic, Rybelsus, Mounjaro, and Victoza should not be presented as interchangeable weight-loss formulary products merely because they contain semaglutide, tirzepatide, or liraglutide. The FDA describes Mounjaro as approved to improve blood-glucose control in adults with type 2 diabetes, while Zepbound is the tirzepatide product labeled for chronic weight management. Product names, indications, and advertising claims must stay distinct.

Should a weight loss clinic offer semaglutide or tirzepatide?

A clinic should compare semaglutide and tirzepatide by labeled indication, target population, operational fit, and supply—not by promising that one product will produce a particular result.

Semaglutide offers broad weight-management labeling through Wegovy, including adults, certain adolescents, cardiovascular-risk reduction, and a specialty MASH indication. FDA also approved Wegovy HD in 2026. The current FDA prescribing information should control the clinic’s clinical and consumer-facing materials because label versions and product information can change.

Tirzepatide offers adult chronic weight-management labeling through Zepbound and an additional indication for moderate-to-severe obstructive sleep apnea in adults with obesity. That OSA indication does not mean every person entering a weight-management program qualifies for an OSA pathway. The clinic would need an appropriate clinical process, documentation, and independently licensed clinician judgment.

Saxenda remains relevant where a clinic needs a liraglutide alternative or an adolescent pathway. Its daily administration may affect workflow design, patient counseling responsibilities, fulfillment coordination, and how the clinic forecasts demand. Those are operational considerations, not instructions about how a clinician should prescribe or how a patient should use a medication.

A useful decision sequence is:

1. 1Define the program population: adults only, adolescents, or both.
2. 2Define the clinical pathways: general weight management or additional labeled pathways.
3. 3Map each pathway to the exact FDA-approved product label.
4. 4Have qualified clinicians and counsel review warnings, contraindications, eligibility, and documentation requirements.
5. 5Check current product availability through FDA’s drug-shortage information and the clinic’s pharmacy relationships.
6. 6Review payer, fulfillment, and state-specific constraints.
7. 7Approve advertising, intake, billing, and patient-support language before launch.

What warnings and label controls belong in the formulary review?

The formulary review should use current FDA prescribing information for each product and should not rely on generalized “GLP-1” copy. Wegovy and Saxenda include boxed warnings concerning potential thyroid C-cell tumors. The Wegovy label also states that coadministration with other semaglutide-containing products or GLP-1 receptor agonists is not recommended; Saxenda includes a corresponding warning against coadministration with other liraglutide-containing products or GLP-1 receptor agonists.

A clinic should create a product-specific review record covering:

• The boxed warning and contraindications.
• The approved population and indication.
• The clinical information the intake and evaluation process must capture.
• The circumstances requiring referral, additional evaluation, or a different care pathway.
• The exact product name used in clinician, pharmacy, website, and billing workflows.
• A process for updating materials when FDA labeling changes.

The business should not turn this review into patient-directed medication advice. Clinical decisions belong to independently licensed clinicians working within their licenses, competencies, and applicable state requirements.

Are compounded semaglutide and tirzepatide FDA-approved?

Compounded semaglutide and tirzepatide are not FDA-approved products, and they should not be treated as equivalent substitutes, generics, or interchangeable versions of approved products. FDA states that compounded drugs do not undergo the agency’s premarket review for safety, quality, or effectiveness and recommends using an FDA-approved product when available and appropriate.

FDA’s April 1, 2026 update stated that, under section 503A, a compounded product generally cannot be an essentially identical copy of a commercially available drug unless the prescriber documents a significant difference for an identified patient. FDA also stated that tirzepatide’s shortage had been resolved and that approved products may be treated as commercially available once shortages are resolved.

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the section 503B bulk-drug-substances list. The proposal was not itself a final rule, and comments were invited through June 29, 2026. Because this is time-sensitive, a clinic should verify the final disposition before relying on any 503B compounding assumption.

The operational default should be an FDA-approved, manufacturer-labeled product. If a clinic considers a compounded-product exception pathway, it should obtain current legal and regulatory review, verify the facility’s status, assess state rules, and document the clinical reason for the pathway. Marketing must never call a compounded product FDA-approved or clinically equivalent to a branded product.

How should a clinic monitor GLP-1 supply and pharmacy relationships?

A clinic should treat supply monitoring as an ongoing operating process rather than a one-time launch decision. FDA’s drug-shortage database is the controlling federal reference for current shortage status, but availability can differ among manufacturers, distributors, and local pharmacies.

A practical supply and pharmacy checklist includes:

• Assigning responsibility for reviewing FDA shortage information.
• Tracking the specific product, presentation, and availability information relevant to the program.
• Establishing a pharmacy escalation process when a prescribed product is unavailable.
• Separating product availability from clinical eligibility.
• Documenting who may change or substitute a product and who must approve that decision.
• Confirming whether prescriptions go to a patient-selected pharmacy or a contracted pharmacy.
• Verifying whether a pharmacy is a 503A pharmacy or FDA-registered 503B outsourcing facility.
• Confirming pharmacy licensure and shipping permissions for each target state.
• Defining recall, adverse-event, lot-information, and pharmacy-substitution procedures.

A platform may help coordinate workflows, but it does not transfer prescribing authority to the business owner or make a pharmacy relationship legally valid in every state. The clinic remains responsible for reviewing its contracts and operating model.

What state rules can change the operating model?

Telehealth, prescribing, ownership, delegation, pharmacy, and corporate-practice rules vary by state. A national formulary decision therefore needs a state-by-state operating matrix rather than a single nationwide assumption.

In California, the Medical Board states that telehealth is a mode of practicing medicine, not a separate form of medicine, and that the practice must be performed by a California-licensed physician while complying with applicable law. The Board also identifies corporate-practice-of-medicine concerns. A non-physician-owned business should obtain California-specific advice about medical-practice ownership, management services, physician control, medical-director arrangements, and advertising.

In Texas, physician delegation of prescriptive authority to an APRN or PA requires a written prescriptive-authority agreement, adequate physician supervision, and registration of the relevant delegation. Outside certain facility-based or underserved settings, Texas generally limits a physician to delegating to no more than seven full-time-equivalent APRNs and PAs. A Texas program should build delegation documentation, chart-review, communication, emergency/referral, and ratio-monitoring processes before assigning clinical responsibility.

In Florida, Board of Medicine materials state that prescribing solely from an electronic questionnaire is not acceptable. The cited rule requires a documented patient evaluation, including history and physical examination sufficient to establish the diagnosis, discussion of treatment options and risks and benefits, and contemporaneous medical records. A Florida intake flow relying only on an automated questionnaire presents a significant compliance concern.

In Oregon, the State Board of Nursing describes Oregon-licensed nurse practitioners as independent practitioners who may diagnose illness and prescribe treatment within their license type, education, population focus, and competency, without a physician collaborative practice agreement. Independence does not eliminate professional accountability, scope-of-practice limits, documentation duties, or organizational requirements.

Colorado law authorizes qualifying APRNs listed on the advanced practice registry and meeting statutory and board requirements to prescribe prescription drugs and controlled substances within their role and population focus. The clinic should verify the individual APRN’s registry status, population focus, prescriptive authority, and applicable requirements.

For broader launch planning, the telehealth-business programs hub and guidance on what a white-label GLP-1 program includes can help separate platform functions from clinical and state responsibilities.

How should GLP-1 weight-loss advertising be reviewed?

Advertising should identify the specific FDA-approved product and avoid implying that every prospect will receive a prescription or achieve a typical result. The FTC’s action involving NextMed addressed allegedly deceptive weight-loss claims, undisclosed costs, fake or manipulated reviews, recurring billing, and cancellation practices. The order underscores the need for competent and reliable evidence for typical-results claims, truthful reviews, clear price disclosures, and informed consent before billing.

Before publication, review each page, advertisement, testimonial, intake screen, and billing flow for:

• Product-specific rather than ingredient-only claims.
• No guaranteed weight-loss language.
• No unsupported typical-results statements.
• Clear separation of consultation, membership, medication, and shipping charges.
• Disclosure that availability and insurance coverage vary.
• No implication that a prescription is guaranteed.
• No claim that compounded medication is FDA-approved or equivalent to an approved product.
• Clear recurring-billing consent and cancellation processes.

The 2024 FTC “click-to-cancel” amendments to the Negative Option Rule are not in force: the U.S. Court of Appeals for the Eighth Circuit vacated them on July 8, 2025, and the FTC’s March 11, 2026 advance notice of proposed rulemaking is only a proposal. The Restore Online Shoppers’ Confidence Act still requires online sellers of recurring plans to clearly disclose material terms before collecting billing information, obtain express informed consent before charging, and provide a simple way to stop recurring charges.

What should a clinic verify before choosing its GLP-1 menu?

Use this review checklist before launch or expansion:

• The proposed products have been matched to current FDA-approved indications.
• Wegovy, Wegovy HD, Zepbound, and Saxenda are distinguished from diabetes-labeled products.
• Current boxed warnings, contraindications, and label restrictions are in the clinical review file.
• A separately reviewed policy addresses compounded products and the current FDA compounding position.
• FDA shortage information is checked on a continuing basis.
• Each pharmacy relationship has been reviewed for licensure, facility status, shipping, recalls, and substitutions.
• Target-state clinician licensure, delegation, evaluation, ownership, and telehealth requirements are documented.
• Website and advertising copy avoids guarantees, unsupported typical results, and patient-directed prescribing promises.
• Billing and recurring-plan disclosures are clear before payment information is collected.
• The business brand is separated from independently licensed clinical decision-making.

MDLaunchr is the brand behind WhiteLabelClinic.com, a white-label telehealth infrastructure platform designed to help qualified businesses evaluate and coordinate the technology, operational, compliance, clinical-network, and fulfillment relationships involved in launching telehealth services. It is one infrastructure option—not a treating clinician, regulator, pharmacy, law firm, or guarantor of product availability or approval. See the GLP-1 weight management program to review how that type of program is set up.

Related reading: Out-of-State Telehealth Provider Registration by State (2026).